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Abstract
Generation of desired cell types by cell conversion remains a challenge. In particular,
derivation of novel cell subtypes identified by single-cell technologies will open up
new strategies for cell therapies. The recent increase in the generation of single-cell
RNA-sequencing (scRNA-seq) data and the concomitant increase in the interest
expressed by researchers in generating a wide range of functional cells prompted us
to develop a computational tool for tackling this challenge. Here we introduce a web
application, TransSynW, which uses scRNA-seq data for predicting cell conversion
transcription factors (TFs) for user-specified cell populations. TransSynW prioritizes
pioneer factors among predicted conversion TFs to facilitate chromatin opening
often required for cell conversion. In addition, it predicts marker genes for assessing
the performance of cell conversion experiments. Furthermore, TransSynW does not
require users' knowledge of computer programming and computational resources.
We applied TransSynW to different levels of cell conversion specificity, which reca-
pitulated known conversion TFs at each level. We foresee that TransSynW will be a
valuable tool for guiding experimentalists to design novel protocols for cell conver-
sion in stem cell research and regenerative medicine.
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1 | INTRODUCTION
Cell conversion is fundamental to many biological processes. Control
of cell conversion has significant relevance in stem cell research. For
example, generation of functionally specific cells by cell conversion is
of clinical interest for cell replacement therapies. However, several
roadblocks need to be overcome for achieving optimal cell conversion,
such as the accurate characterization of cell populations and the iden-
tification of cell conversion factors. Single-cell RNA-sequencing
(scRNA-seq) technologies have made it possible to address these
challenges. Due to the greater amount of scRNA-seq data generated
across the world, experimental researchers are increasingly expressing
their interest in deriving novel functional cell types.
Here, we present TransSynW, a scRNA-seq based web applica-
tion for identifying cell conversion transcription factors (TFs) applica-
ble in stem cell and clinical research (Figure 1A). It prioritizes pioneer
factors (PFs) in the prediction of conversion TFs. Evidence suggests
that PFs have a key role in chromatin opening, a process often
required for cell conversion.1 Indeed, including PFs on cell conversion
protocols has been shown to improve their outcome.1 Furthermore, it
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predicts marker genes for each target cell type, enabling researchers
to assess the fidelity of experimentally converted cells. In addition, it
is user-friendly, and it does not require users' computer programming
or computational resources. We also created a comprehensive video
tutorial for guiding users through the web interface.
The application of TransSynW to various cell systems well-
recapitulated known cell conversion TFs and made novel predictions,
including the phenotypic conversion between cells in organoids and their
in vivo counterparts. Moreover, predicted marker genes were consistent
with experimentally known ones. These results highlight the applicability
of TransSynW to a wide range of cell conversion experiments.
2 | RESULTS
2.1 | Method overview
The TransSynW algorithm first identifies specifically and nonspecifically
expressed TFs, and selects the combination that exhibits the highest
synergistic interactions among them (see Methods) (Figure 1B). Nota-
bly, here we considered for the nonspecific part only PFs that have pre-
viously been reported to be involved in cell conversion protocols
(Table S1). Predicted conversion TFs are then ranked by the expression
fold change between the target and starting cell populations and users
can prioritize the TFs for experimental follow-ups based on this ranking.
(A)
(B)
F IGURE 1 A, Application of TransSynW to stem cell research and regenerative medicine. B, Schematic overview of TransSynW algorithm
(see also Methods). First, transcription factors (TFs) most specifically expressed in the selected target cell population (specific TFs) and
nonspecifically expressed pioneer factors (PFs) are computed. The most synergistic combination of specific TFs and nonspecific PFs is then
identified. The predicted set of TFs are ranked by expression fold change between target and starting cell populations. In parallel, top
10 candidate marker genes for target cell population are computed by JSD
Significance Statement
The manuscript proposes a computational web application,
TransSynW. To our knowledge, it is the only computational
tool that can identify cell conversion transcription factors
(TFs) for any cell population in single-cell RNA-sequencing
data. TransSynW does not require prior biological informa-
tion, computer programming, and users computational
resources. In addition, TransSynW prioritizes pioneer factors
among predicted conversion TFs to facilitate chromatin
opening often required for cell conversion. Furthermore,
TransSynW predicts marker genes for assessing the perfor-
mance of cell conversion experiments. Thus, TransSynW will
be a staple tool for guiding experimentalists to design novel
protocols for cell conversion in stem cell research and
regenerative medicine.
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We compiled the scRNA-seq data of starting cell types frequently used
in cell conversion experiments from various scRNA-seq platforms
(Table S2). For optimal results, users are recommended to use starting
and target cell type data obtained from the same scRNA-seq platform
or, if not available, from the closest sequencing platform. In general, it is
recommended to select at least one PF and one specific TF from the
predicted conversion TFs. It may be advisable to select more factors if
the phenotypic difference between the starting and target cell types is
large. Finally, TransSynW also predicts potential marker genes of the
target cell populations. This feature enables researchers to select
markers for assessing the performance of their cell conversion
experiments.
TABLE 1 Predicted specific transcription factors (TFs) and nonspecific PFs





(1) Conversion into broad cell type
Myoblast MYF5, MYOD1, PAX7, GLIS3, PAX3 CEBPB, IRF8, PBX1 1,3,4,5,7 30283141
Keratinocyte TRP63, GATA3, NFIB KLF4, GRHL2, CEBPA 0-16 30283141
Cardiomyocyte NKX2-5, TBX5, PROX1, ZFP579, NR0B2 GATA4, MEIS1, PBX1 9,14 30283141
Hepatocyte NR1I2, ZFP750, ZFHX4, HNF1A, ZBTB48 HNF4A, FOXA3, FOXA2 4,5,10,11,12,15 30283141
HSC HLF, HOXA9, GATA2, TAL1, MYCN CEBPB, CEBPA, PBX1 0,4,8 30283141
Neuron EOMES, NEUROD6, EGR4, RARB, DLX6 FOXG1, NEUROD1, PBX1 9,10,12 30283141
Oligodendrocyte/OPC NKX6-2, OLIG1, SOX10, OLIG2, NFE2L3 SOX2 0,6,11 30283141
Macrophage RUNX3, BATF3, BATF, NFE2, E2F1 SPI1, CEBPA, ARID3A Different tissues 30283141
Beta cell NKX6-1, PDX1, MAFA, OVOL2, MNX1 NEUROD1, ISL1, FOXA2 0,8,9,11,17 30283141
NSC ZFP275, ASCL1, TCF3 FOXG1, SOX2, PBX1 All young NSCs 30827680
(2) Conversion into subtype
Dopaminergic neuron NPAS4, MYT1L, EBF3, POU6F1, BNC2 FOXA2, ASCL1, GATA3 hDA 27716510
Medial floorplate progenitor LMX1A, SP2, NR2F6, LMX1B, HMGA2 FOXA2, ASCL1, SOX2 hProgFPM 27716510
GABAergic neuroblast GATA3, SOX14, MYT1L, BNC2, ZBTB38 ASCL1, SOX2, PBX1 hNbGaba 27716510
Oculomotor neuron PHOX2B, PHOX2A, ISL1, RXRG, NR2F2 FOXA2, ASCL1, “PBX1 hOMTN 27716510
Serotonin neuron FEV, GATA3, SOX1, DPF1, LMX1B GATA2, PBX1 hSert 27716510
CD4+ central memory T cell RBSN, RFX3, NR4A1, KLF9, ID3 GATA3, CEBPB TCM 29352091
CD8+ memory T cell EOMES, BACH2, KLF7, MYC, ID3 CEBPB, GATA3 4,6,11,13 31754020
Memory B cell KLF13, LMO4, PCBD1, KLF10, ZBTB38 IRF8, SPI1, CEBPB Memory B cell 31968262
(3) Phenotype conversion
Primed mESC 1 LIN28A, MYC, ID1, FOXP1, ID3 POU5F1, ESRRB, KLF4 FBSLIF 25471879
Naive mESC 1 ZFHX2, MEIS2, ZIC2 POU5F1, ESRRB, KLF4 2iLIF
Primed mESC 2 LIN28A, FOXP1, SOX4 SOX2, POU5F1, KLF4 mES_lif 26431182
Naive mESC 2 SPIC, MITF, MEIS2 ESRRB, KLF4, POU5F1 mES_2i
Active NSC CENPS, EGR1, INSM1, MXD3, E2F1 ASCL1, SOX2, PBX1 All young aNSCs 30827680
Quiescent NSC DBP, EPAS1, ID2 FOXG1, PBX1, ASCL1 All young qNSCs
Fetal hepatocyte ZGPAT, KLF11, ZBTB20 GATA4, HNF4A, CEBPA Fetal hepatocyte 30500538
Organoid hepatocyte HES6, LEF1, THAP8, SOX9, HTT FOXA2, HNF4A, MEIS1 Fetal hepatocyte
organoid
Adult hepatocyte 1 KLF9, CEBPD, KLF6 FOXA2, HNF4A, CEBPB Hepatocyte 31292543
Adult hepatocyte 2 SCAND1, NR3C1, EDF1 HNF4A, FOXA2, PBX1 Hepatocyte 30348985
Adult excitatory neuron MLXIPL, PEG3, HLF, BHLHE40, KLF9 FOXG1, CEBPB, PBX1 adult_Ex 31619793
Organoid excitatory neuron NEUROG2, SOX11, SOX4, CSRP2,
CARHSP1
FOXG1, PBX1 hOrga_EN
Adult inhibitory neuron PEG3, MLXIPL, HLF, PPARGC1A, KLF9 FOXG1, SOX2, PBX1 adult_In 31619793
Organoid inhibitory neuron SIX3, PAX6, ID4, KLF10, MEIS2 ASCL1, SOX2, SOX9 hOrga_IN
Note: Experimentally validated conversion TFs are marked in bold. TFs are ordered from left to right by fold change to MEF/HFF. Cluster IDs annotated to
same cell types in PanglaoDB were merged prior to analysis. Macrophage data from different tissues (heart, kidney, lung, muscle, brain, pancreas, skin
spleen, trachea) were merged. See Table S3 for literature evidence for predicted conversion TFs.
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2.2 | Application to various cell conversions
To demonstrate the applicability of TransSynW, we applied it to dif-
ferent cell systems, which encompassed conversions into broad cell
types, subtypes, and phenotypic states (Tables 1 and S3). For example,
in the first category, FOXA2, FOXA3, and HNF4A were predicted for
the hepatocyte, which, together with HNF1A predicted in the specific
part, are known for hepatocyte conversion.2 The predicted TFs for
the beta cells included NKX6-1, MAFA, PDX1, and NEUROD1, which
have been shown to induce beta cell conversion.3-5 Moreover, in both
cases the predicted marker genes recapitulated commonly used ones
(Tables 2 and S4). Indeed, many predicted conversion TFs are known
to regulate each other and the predicted marker genes (Figure 2A,B),
supporting the biological relevance of synergistic interactions cap-
tured by TransSynW.
Next, we analyzed different subtypes of neurons, as they are one
of the most well studied subtypes. Among the predicted TFs for dopa-
minergic (DA) neurons, MYT1L, ASCL1, FOXA2, and GATA3 have
TABLE 2 Predicted marker genes with documented evidence
Cell type Predicted marker gene with evidence Reference (PubMed ID or website)
(1) Conversion into broad cell type
Myoblast CALCR, FGFR4, DES, ANKRD1, FITM1 12223412, 26440893, 26492245,
24644428, 8120103
Keratinocyte KRT5 22028850
Cardiomyocyte NPPA, MYH6 27123009, https://www.rndsystems.
com/cn/research-area/cardiac-stem-
cell-markers
Hepatocyte SRD5A2, FGF21 25974403, 28515909






Neuron HTR2C, NTNG1, HS6ST3 30078709
Oligodendrocyte/OPC MAG, CLDN11, PLEKHH1, ASPA, TRF 29024657
Macrophage FOLR2, F13A1, LYZ2, PF4, MGL2, MMP13,
CLEC10A
28576768, 29622724, 25477711,
Beta cell INS1, INS2, G6PC2 22745242, 15133852, 25322827
NSC NUDC, TUBA1B, TUBA1A 21771589, 29057214, 29281841
(2) Conversion into subtype
Dopaminergic neuron ALDH1A1, TH 30096314, http://www.abcam.com/
neuroscience/neural-markers-guide
Medial floorplate progenitor WNT1, MDK 31080111, 24125182, 11750071
GABAergic neuroblast GAD2 http://www.abcam.com/neuroscience/
neural-markers-guide
Oculomotor neuron PRPH, FGF10, SLIT3, EYA1 24549637, 9221911, 20215354,
31080111
Serotonin neuron TPH2, SLC6A4 http://www.abcam.com/neuroscience/
neural-markers-guide
CD8+ memory T cell SELL, CXCR5, DRC1 29236683, 18000950, 30243945
Memory B cell TNFRSF13B, CD27 Company ebioscience, miltenyibiotec
(3) Phenotype conversion
Primed mESC 1 BMP4 26860365
Active NSC CENPF 29727663
Quiescent NSC GJA1 29727663
Fetal hepatocyte FGB, CYP2E1 28166538, 29622030
Adult hepatocyte 1 CYP3A4 26838674
Adult hepatocyte 2 APOA1 28166538
Adult excitatory neuron CCK 12815247
Adult inhibitory neuron CCK, PVALB, CRH 12815247, 2196836, 2843570
Note: See Table S4 for full list of predicted marker genes.
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been shown to generate DA neurons.6-8 The predicted TFs for the
medial floorplate progenitor, LMX1A and FOXA2, are consistent with
the previous attempt to derive this cell subtype.9 ASCL1 is sufficient
to convert fibroblasts into GABAergic neurons.10 Consistently, the
predicted TFs for GABAergic neuroblasts contained ASCL1 and no





F IGURE 2 Transcriptional regulatory interactions among predicted conversion transcription factors (TFs) and marker genes for, A, hepatocyte
and B, beta cell. Interaction data were retrieved from MetaCore from Clarivate Analytic in May/2020. C, Experimental strategy to improve cell
conversion protocols for GABAergic neurons (Gaba) and medial floorplate progenitor (ProgFPM) based on TransSynW predicted core TFs. Dashed
outlines represent nonvalidated TFs in the literature. D, Processing time vs number of cells in input scRNA-seq file (n = 3). Target population size was
fixed to 8% of total size. E, Processing time for Rds files vs number of cells in target population (n = 3). Input population size was fixed to 10 000
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TFs for oculomotor neuron included ISL1, PHOX2A, and PHOX2B
which have been reported to generate motor neurons via a synergistic
interaction.11,12 FEV, GATA2, and LMX1B were predicted for seroto-
nergic neurons, which are among the TFs used for deriving this cell
subtype.13 We considered memory T and B cells as subtypes of their
naive counterparts. Although a defined set of TFs for generating T
cells has not been reported, the nonspecific PFs for both CD4+ and
CD8+ T cells contained GATA3 and CEBPB, suggesting that these fac-
tors are primary candidates for experimental validation. Indeed,
GATA3 is implicated in CD8+ memory T cell conversion.14 Among the
specific TFs, ID3, MYC, BACH2, and EOMES are reported to initiate
CD8+ memory T cell conversion.15-17 The known marker genes, such
as SELL and CXCR5, were also identified. Finally, the nonspecific PFs
for the memory B cells included IRF8 and SPI1, which together are
implicated in the generation of B cell memory.18
Another type of cell conversion is phenotypes of a same cell type.
The predicted nonspecific PFs for the two mouse embryonic stem
cells (mESC) datasets are known to induce pluripotency.19-21 The spe-
cific conversion TFs predicted for both primed mESC populations
were LIN28A and FOXP1. LIN28A is known to induce the transition
from naive to primed mESCs.22 FOXP1 is implicated in maintaining
pluripotency under non-2i conditions.23 Whether FOXP1 induces a
transition from a naive state to a primed state calls for further investi-
gations. MEIS2 was predicted for both naive mESC populations. Little
is known about its role in mESC regulation and hence it constitutes a
novel candidate gene. The nonspecific conversion PFs for both active
(aNSCs) and quiescent (qNSCs) consisted of known NSC-conversion
TFs (eg, ASCL1, SOX2, FOXG1). The specific TFs for aNSCs contained
EGR1 known to activate EGFR and accelerate proliferation of NSCs,24
and E2F1, which is a cell cycle regulator linked to EGFR signaling in
NSCs.25 The conversion TFs for qNSCs included ID2, a BMP effector
that has been inferred to regulate qNSCs.26 Furthermore, CENPF and
GJA1 are implicated as markers for late-aNSCs and qNSCs, respec-
tively.27 Next, the scRNA-seq data of organoid28 and in vivo hep-
tocytes28-30 were analyzed. The nonspecific PFs included general
hepatocyte conversion TFs (eg, HNF4A, FOXA2, GATA3). Among the
specific TFs for the in vivo hepatocytes were ZBTB20, KLF6, KLF9,
CEBPD, and NR3C1. ZBTB20, KLF9 are important for hepatocyte
proliferation,31 whereas KLF6, CEBPD, KLF9, and NR3C1 regulate
hepatic glucose and lipid metabolism,32-34 suggesting that the deriva-
tion of in vivo hepatocytes might require sustained cell proliferation
and proper metabolization of glucose and lipids. Known hepatocyte
marker genes, such as FGB, CYP2E1, CYP3A4, APOA1, were
predicted only for the in vivo hepatocytes but none for the in vitro
ones. Finally, TransSynW was applied to in vivo and organoid excit-
atory and inhibitory neurons.35 TFs predicted only for the in vivo
excitatory and inhibitory neurons contained many common TFs
(PEG3, KLF9, HLF, and MLXIPL), suggesting a common maturation
mechanism. KLF9 is known to be necessary for late-phase matura-
tion of neurons.36 BHLHE40, which was only predicted for the
in vivo excitatory neurons, is implicated in the regulation of neuronal
excitability.37 Moreover, a few known markers (CCK, PVALB, CRH)
for excitatory/inhibitory neurons were predicted only for the
adult samples. It would be of interest to experimentally test if
predicted conversion TFs could indeed convert organoid cells into
functional ones.
Taken together, we demonstrated that TransSynW can be effec-
tively applied for identifying conversion TFs for a wide range of cell
types. An example experimental strategy for using TransSynW
predicted conversion TFs is shown in Figure 2C.
2.3 | Processing speed
The processing speed of TransSynW was assessed using text file, Rds
file and a sparse matrix saved as Rds file (sparse-Rds). The time
required for the upload of the data was not considered for this analy-
sis. Thus, depending on the users internet connection speed, the over-
all processing time may vary to a certain degree. Rds files were the
most efficient in processing 10 000 cells (6 minutes) (Figure 2D). In
addition, up to 40 000 cells were successfully processed with Rds
files, whereas only 25 000 cells in the other formats. This is in accor-
dance with the respective file sizes (Table S5). If users wish to use
datasets larger than 40 000 cells, we recommend to down-sample
them. Next, we benchmarked the execution time against the target
cell population size in 10 000 cells. The processing time peaked at
11 minutes for 3500 cells (Figure 2E). Afterwards, it started decreas-
ing due to the reduced size of the background populations. Our gen-
eral recommendation to users is to use Rds files for datasets with
more than 10 000 cells.
3 | DISCUSSION
We have introduced a scRNA-seq based web application, TransSynW,
for unbiased identification of cell conversion TFs, following the
increasing interest from experimental researchers in generating novel
functional cell types identified by scRNA-seq. TransSynW does not
require prior biological knowledge, computer programming and com-
putational resources. Moreover, TransSynW identifies potential
marker genes for target cell types, which researchers can use for
assessing the performance of conversion experiments. Furthermore,
prioritization of PFs well recapitulated known conversion TFs in vari-
ous systems, and predicted novel ones. We foresee that TransSynW
will be a valuable tool for the experimental community, particularly for
the generation of novel cell populations for stem cell research and
regenerative medicine purposes.
4 | MATERIALS AND METHODS
4.1 | Implementation
TransSynW is written in HTML, JavaScript (frontend), PHP and
Bash (backend), and runs on a virtual server hosted by Luxembourg
Centre of Systems Biomedicine (LCSB, University of Luxembourg).
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The frontend allows users to upload all required data, which are then
parsed to the backend as different variables. In the backend bash
script, the variables are parsed to the TransSynW main R script as
different arguments. The output files are compressed into a .zip folder
and sent to the user-specified E-mail address.
4.2 | Identification of conversion TFs
The main algorithm is based on the notion that conversion TFs consist
of a combination of TFs that are specifically expressed in a target pop-
ulation and TFs that are more broadly expressed in the background
population, and that these TFs synergistically interact with each
other.38 The algorithm follows four major steps.
• Step 1: Identification of candidate TFs.
TransSynW first normalizes the data by the total RNA counts. Then
TFs whose expression value is 0 across all cells in the target cell
population are discarded. Next, it selects top 300 lowest CV (coef-
ficient of variation) TFs as potential candidate TFs, since using
more than this number of TFs often resulted in an out-of-memory
error during the subsequent computation and conversion TFs usu-
ally exhibit low expression variation.
• Step 2: Identification of most specifically expressed TFs.
The set of TFs that are specifically expressed in the target popula-
tion is determined by Jensen-Shannon Divergence (JSD). JSD is
computed for each TF in each cell and the summed JSD value for
each TF over all cells is calculated. The top 10 lowest summed-JSD
TFs are selected as the most specifically expressed TFs.
• Step 3: Identification of most synergistic set of specifically expressed TFs.
Next, TransSynW identifies the most synergistic subset of TFs among
the most specifically expressed TFs by computing MMI.39
MMI Sð Þ= −
X
T⊆S
−1ð Þ Tj jH Tð Þ,
where S = {X1, X2, …, Xk}, T is a subset of S, jTj denotes the cardinal-
ity of T, and H is Shannon's entropies. Negative MMI values imply
a synergistic interaction among the TFs.39 TransSynW first com-
putes MMI of all sets of three TFs among the most specifically
expressed TFs. Then a new TF is added to this set and MMI is com-
puted again. If MMI is synergistic, then the next TF is added to the
previous set, and so on. This iteration continues until either MMI
no longer shows synergy, or when the maximum core size is
reached. Here, the maximum core size was set to five.
• Step 4: Addition of PFs.
The specific TF set from step 3 is extended with the nonspecific part,
consisting solely of PFs. Every subset of three PFs is added to the
specific part. MMI is computed for each set of all TFs and the most
synergistic combination is selected as the final conversion TF set.
The final conversion TFs are ranked by the expression fold
change calculated between the target cell population and starting cell
population.
4.3 | Identification of marker genes
The marker gene set (Table S6) was collected from the following
sources; extracellular proteins and membrane receptors,40 cytoskele-
tal genes (http://www.informatics.jax.org/), metabolic genes (https://
www.vmh.life/#human/all) and CD markers for immune cells (www.
abcam.com/CDmarkers). These genes are relatively easily accessible
for experimental validation. TransSynW identifies the top 10 candidate
marker genes among this compiled set by computing JSD. Literature
evidence for predicted markers were collected either manually or
from CellMarker (http://biocc.hrbmu.edu.cn/CellMarker/).
4.4 | PF set
Information on PFs that have previously been reported to be involved
in cell conversion protocols was manually collected from literature.
The list is available in Table S1.
4.5 | scRNA-seq data of starting cell populations
scRNA-seq data of starting cell types were collected from Cell Ranger,
GEO and Array Express databases, log 2 transformed and mean gene
expression was calculated and compiled in TransSynW (Table S2).
4.6 | scRNA-seq dataset of target cell populations
scRNA-seq data used in this study were obtained from the following
sources.29-31,35,41-48 For References 43, 48, the reprocessed data
were retrieved from PangloaDB,49 as the cell annotation was more
accurate than the original one.
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